Evidence map›Paper›PMID 37063879›Full record

ReviewFrontiers in immunology2023

Controversial role of ILC3s in intestinal diseases: A novelty perspective on immunotherapy.

Yunshu Zhang, Xuefei Feng, Juan Chen, Jiahao Liu, Jianmin Wu, Hongpei Tan, Ze Mi, Pengfei Rong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Alterations in mucosa branchedGut microbes · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yunshu ZhangDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xuefei FengDepartment of Government & Public Administration, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Juan ChenDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jiahao LiuDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jianmin WuDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hongpei TanDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ze MiDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Pengfei RongDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNChinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ILC3s have been identified as crucial immune regulators that play a role in maintaining host homeostasis and modulating the antitumor response. Emerging evidence supports the idea that LTi cells play an important role in initiating lymphoid tissue development, while other ILC3s can promote host defense and orchestrate adaptive immunity, mainly through the secretion of specific cytokines and crosstalk with other immune cells or tissues. Additionally, dysregulation of ILC3-mediated overexpression of cytokines, changes in subset abundance, and conversion toward other ILC subsets are closely linked with the occurrence of tumors and inflammatory diseases. Regulation of ILC3 cytokines, ILC conversion and LTi-induced TLSs may be a novel strategy for treating tumors and intestinal or extraintestinal inflammatory diseases. Herein, we discuss the development of ILCs, the biology of ILC3s, ILC plasticity, the correlation of ILC3s and adaptive immunity, crosstalk with the intestinal microenvironment, controversial roles of ILC3s in intestinal diseases and potential applications for treatment.

Indexed as

Intestinal DiseasesNeoplasmsCytokinesHumansImmunity, InnateImmunotherapyLymphocytesTumor MicroenvironmentCytokinescancerinflammatory diseaseinnate lymphocyte cellintestine homeostasisplasticitysecondary lymphoid organtertiary lymphoid tissuetranscription factor

Identifiers

PMID37063879
PMCPMC10090672
OpenAlexW4361293018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.